Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Intersect ENT.

    Client Virtual Booth

    INTERSECT ENT

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Intersect ENT
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1555 Adams Drive Menlo Park, CA 94025
    Telephone
    Telephone
    650.641.2100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.intersectent.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/intersect-ent/
    Twitter
    Twitter
    https://twitter.com/IntersectENT

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medtronic Completes Acquisition of Intersect ENT

    Details:

    Medtronic has acquired Intersect ENT's PROPEL™ and SINUVA™ (mometasone furoate) sinus implant product lines and technology, intellectual property, and Menlo Park, Calif., facility.


    Lead Product(s): Mometasone Furoate

    Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Propel

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Medtronic Plc

    Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million

    Deal Type: Acquisition May 13, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medtronic to Acquire Intersect ENT

    Details:

    Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing.


    Lead Product(s): Mometasone Furoate

    Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Propel

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Medtronic Plc

    Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million

    Deal Type: Acquisition August 06, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search